David R. Rahn & Associates Inc. Eli Lilly & CO Transaction History
David R. Rahn & Associates Inc.
- $236 Million
- Q1 2024
A detailed history of David R. Rahn & Associates Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, David R. Rahn & Associates Inc. holds 5,600 shares of LLY stock, worth $5.07 Million. This represents 1.85% of its overall portfolio holdings.
Number of Shares
5,600
Previous 5,600
-0.0%
Holding current value
$5.07 Million
Previous $3.26 Million
33.46%
% of portfolio
1.85%
Previous 1.4%
Shares
3 transactions
Others Institutions Holding LLY
# of Institutions
3,719Shares Held
738MCall Options Held
7.09MPut Options Held
7.24M-
Lilly Endowment Inc Indianapolis, IN98.9MShares$89.5 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA72.7MShares$65.9 Billion1.14% of portfolio
-
Black Rock Inc. New York, NY65.3MShares$59.1 Billion1.2% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA51.4MShares$46.6 Billion27.92% of portfolio
-
State Street Corp Boston, MA34.3MShares$31 Billion1.21% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $860B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...